LLY vs. NVDA: Eli Lilly vs. NVIDIA Stock Comparison

Performance

Cumulative Growth

Trailing Returns

Performance at a Glance

Risk

Drawdown

NVIDIA (NVDA) has a highly aggressive beta of 2.20, indicating much higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.51 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk at a Glance

Company Profile

Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas NVIDIA (NVDA) belongs to Information Technology (Semiconductors & Semiconductor Equipment) — their GICS classifications point to very different parts of the market.

Valuation

NVIDIA (NVDA) at 31.42 sits in the cheaper P/E ratio quartile, while Eli Lilly (LLY) at 40.32 is closer to its industry’s usual earnings multiple — a discount for NVDA, though growth and earnings durability still matter.

On P/S ratio, both Eli Lilly (LLY) at 13.98 and NVIDIA (NVDA) at 19.61 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both look rich against book: NVIDIA (NVDA) at 25.43 sits in the upper P/B ratio quartile, and Eli Lilly (LLY) at 32.45 prices even higher, above its industry range.

Valuation at a Glance

Profitability

Both Eli Lilly (LLY) at 107.46% and NVIDIA (NVDA) at 114.29% turn shareholders’ equity into profit at rates above their industry benchmark ranges for ROE. That is a strong capital-efficiency signal, though leverage and the equity base still matter.

Both Eli Lilly (LLY) at 34.99% and NVIDIA (NVDA) at 62.97% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Eli Lilly (LLY) at 49.39% and NVIDIA (NVDA) at 65.60% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability at a Glance

Growth

Revenue Growth

Revenue Growth at a Glance

EPS Growth

EPS Growth at a Glance

Financial Strength

NVIDIA (NVDA) at 3.44 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.50 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.

NVIDIA (NVDA) at 0.07 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.39 uses more debt funding than most peers.

Financial Strength at a Glance

Dividends

NVIDIA (NVDA) at 0.49% earns its spot in the top quartile of its industry’s yields; Eli Lilly (LLY) at 0.61% is past the top of its own peer range — territory where a dividend-safety check matters more than the headline number.

NVIDIA (NVDA) at 0.61% keeps its payout in the industry’s typical band, while Eli Lilly (LLY) at 22.13% pays out more than any of its peers — the most stretched cover in its group.

Dividends at a Glance